Teva to appeal against invalidation of Copaxone patents

Teva will appeal against a decision which saw the invalidation of four patents covering its multiple sclerosis drug Copaxone (glatiramer acetate injection).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Teva suffers defeat as Copaxone claims invalidated

27 October 2017 The English High Court has invalidated two patent claims protecting Copaxone (glatiramer acetate), a billion-dollar drug marketed by Teva.

Big Pharma

Teva sues nine companies for Copaxone patent infringement

23 December 2016 Teva has filed a complaint against nine pharmaceutical companies including Dr Reddy's Laboratories, Sandoz and Mylan for alleged patent infringement over Copaxone, a treatment for patients with multiple sclerosis.

More on this story

Big Pharma

Teva suffers defeat as Copaxone claims invalidated

27 October 2017 The English High Court has invalidated two patent claims protecting Copaxone (glatiramer acetate), a billion-dollar drug marketed by Teva.

Big Pharma

Teva sues nine companies for Copaxone patent infringement

More on this story

Big Pharma

Teva suffers defeat as Copaxone claims invalidated

27 October 2017 The English High Court has invalidated two patent claims protecting Copaxone (glatiramer acetate), a billion-dollar drug marketed by Teva.

Big Pharma

Teva sues nine companies for Copaxone patent infringement